The BCR::ABL1 transcript detection and quantification in peripheral blood (PB) cells using reverse transcription-quantitative PCR (RT-qPCR) and normalization to a housekeeping gene is recognized as the international standardized method for determining minimal residual disease (MRD) and plays an important role in the management of CML patients [19,20]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.